News | November 06, 2025
Teva reports 11th consecutive quarter of growth
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Budesonide is indicated for mild to moderate active Crohn's disease involving the ileum and/or the ascending colon in adults and children 8 years of age and olde
Upon completion, Kimberly-Clark shareholders are expected to own about 54% of the combined entity, while Kenvue shareholders will hold the remaining 46%
Revenue for the quarter rose 5.8% to Rs. 1,487 crore as compared to Rs. 1,406 crore in the corresponding quarter of the previous fiscal
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
With over two decades of extensive experience, Lal has established himself as a transformational leader in the FMCG and consumer goods sectors
Performance driven by growth portfolio momentum, pipeline advancements, and strategic business development
Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
New AI capabilities will help scientists identify, optimize, and validate new molecules. Additional applications include manufacturing, medical imaging, and enterprise AI agents
Subscribe To Our Newsletter & Stay Updated
